Latest Healthtech Startup Funding Rounds
Companies building technology for healthcare delivery, diagnosis, clinical workflows and patient access.
- Rounds
- 753 Jan 1 – Oct 25, 2026
- Disclosed funding
- $25.9B 612 disclosed amounts
- Median round
- $16M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
 Accro BioscienceCompany profile Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease. Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease. | $50M | Series CSeries C+ | Healthtech, Biotech | United States | Investors | |
| KH Kin HealthCompany profile Records medical appointments and translates them into plain-language summaries for patients to act on Records medical appointments and translates them into plain-language summaries for patients to act on | $9M | Seed | Healthtech | United States | Investors | |
| FT Full-Life TechnologiesCompany profile Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing | $150M | Series D+DebtUndisclosed | Healthtech, Biotech | China | Investors | |
| VT Violet TherapeuticsCompany profile Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform | $4.8M | Seed+Seed | Healthtech, Biotech | United States | Investors | |
 AlcolaseCompany profile Alcolase is developing a liposomal enzyme system intended to break down alcohol in the stomach before absorption. Alcolase is developing a liposomal enzyme system intended to break down alcohol in the stomach before absorption. | €1.5M | Undisclosed | Healthtech, Biotech | Denmark | Investors | |
| WB Wonderlab BioCompany profile Makes off-the-shelf iPSC-derived cell therapies using HLA-matched super donors for broad patient access Makes off-the-shelf iPSC-derived cell therapies using HLA-matched super donors for broad patient access | Undisclosed | StrategicUndisclosed | Healthtech, Biotech | United States | Investors | |
| CM CREATE MedicinesCompany profile Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies | $122M | Series B | Healthtech, Biotech | United States | Investors | |
| O OpturaCompany profile Provides ROAI platform for healthcare organizations to assess AI business value and viability Provides ROAI platform for healthcare organizations to assess AI business value and viability | $17.5M | Series A | Healthtech | United States | Investors | |
| DT Degron TherapeuticsCompany profile Develops molecular glue degrader medicines targeting previously undruggable proteins Develops molecular glue degrader medicines targeting previously undruggable proteins | $40M | Series A+Series A | Healthtech, Biotech | China | Investors | |
| BM Butterfly MedicalCompany profile Develops a minimally invasive implantable device to treat benign prostatic hyperplasia in men Develops a minimally invasive implantable device to treat benign prostatic hyperplasia in men | $21M | Series CSeries C+ | Healthtech | Israel | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.